The Biosensis proNGF RapidTM enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the quantification of full-length proNGF protein in less than 4 hours in human serum, heparin-plasma, cell supernatants and cell lysates only if used as directed. Please refer to the kit protocol for specific use instructions for each substrate application.
This ELISA kit consists of a pre-coated anti-proNGF capture antibody, a biotinylated anti-proNGF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of proNGF present in samples and protein standards. A human proNGF positive control (QC sample) is provided to assure consistent assay performance.
This proNGF ELISA kit contains a recombinant human proNGF standard expressed in E.coli. This ELISA kit does not cross-react with the mouse form of proNGF, and due to sequence homology of mouse and rat proNGF is not expected to detect rat proNGF. The antibodies used in this ELISA kit bind epitopes within the pro-domain of the protein and therefore recognize proNGF and the pro-domain peptide, but do not cross-react with mature NGF!
Note that accurate proNGF quantification in human serum requires the addition of Heterophilic Antibody Blocker BL-003-1000 provided in the kit, and available for purchase separately.
This kit has not been tested for other applications. Sufficient amount of proNGF standard is supplied to allow for spike- and recovery experiments in order to validate this ELISA assay for other sample matrices if required. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.
Alternative Namespro-beta nerve growth factor; proNGF; NGF
Application(s)ELISA
SpecificityHuman. Does not react with mouse proNGF, and is not expected to detect rat proNGF. Does not cross-react with recombinant human NGF and proBDNF tested at 25 ng/mL.
Species ReactivityHuman
Immunogen DescriptionRecombinant human, wild-type proNGF protein, made in E.coli
Range0.078 - 5 ng/mL
SensitivityTypical limit of detection (LOD) for proNGF is <60 pg/mL determined as blank value plus 3x standard deviation of blank OD (n=10).
The Biosensis proNGF RapidTM enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the quantification of full-length proNGF protein in less than 4 hours in human serum, heparin-plasma, cell supernatants and cell lysates only if used as directed. Please refer to the kit protocol for specific use instructions for each substrate application.
This ELISA kit consists of a pre-coated anti-proNGF capture antibody, a biotinylated anti-proNGF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of proNGF present in samples and protein standards. A human proNGF positive control (QC sample) is provided to assure consistent assay performance.
This proNGF ELISA kit contains a recombinant human proNGF standard expressed in E.coli. This ELISA kit does not cross-react with the mouse form of proNGF, and due to sequence homology of mouse and rat proNGF is not expected to detect rat proNGF. The antibodies used in this ELISA kit bind epitopes within the pro-domain of the protein and therefore recognize proNGF and the pro-domain peptide, but do not cross-react with mature NGF!
Note that accurate proNGF quantification in human serum requires the addition of Heterophilic Antibody Blocker BL-003-1000 provided in the kit, and available for purchase separately.
This kit has not been tested for other applications. Sufficient amount of proNGF standard is supplied to allow for spike- and recovery experiments in order to validate this ELISA assay for other sample matrices if required. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.
Application DetailsELISA. For the quantification of Nerve growth factor, pro- (proNGF) in Serum, Plasma (Heparin), Culture Supernatant, Cell Lysates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
TargetNerve growth factor, pro- (proNGF)
SpecificityHuman. Does not react with mouse proNGF, and is not expected to detect rat proNGF. Does not cross-react with recombinant human NGF and proBDNF tested at 25 ng/mL.
Target Cross-Reactivity (ELISA)Does not cross-react with recombinant human NGF and proBDNF tested at 25 ng/mL.
Target Host SpeciesHuman
Species ReactivityHuman
Immunogen DescriptionRecombinant human, wild-type proNGF protein, made in E.coli
Range0.078 - 5 ng/mL
SensitivityTypical limit of detection (LOD) for proNGF is <60 pg/mL determined as blank value plus 3x standard deviation of blank OD (n=10).
Scientific BackgroundNerve growth factor (NGF) is synthesized as a precursor (proNGF) which may be released and have physiological functions to cause cell death. It binds neurotrophin receptor p75 and sortilin and may also be important for the development of nervous system. proNGF is synthesized in target tissues and glia, transported retrogradely and may be released.
Shipping StatementFor order quantities larger than 1 plate, this product is supplied in package units of 2 plates.
This standard curve generated in our laboratories is for demonstration purposes only, but can be used as a guide to expected performance. A standard curve should be generated for each assay.
Loch AA et al. (2023). Plasma levels of neurotrophin 4/5, NGF and pro-BDNF influence transition to mental disorders in a sample of individuals at ultra-high risk for psychosis Psychiatry Res. [Epub ahead of print]. Application: Human plasma (EDTA).
Marsland M et al. (2023). ProNGF Expression and Targeting in Glioblastoma Multiforme. Int J Mol Sci. 24(2):1616 Application: Human plasma.
March B et al. (2021). ELISA-based quantification of neurotrophic growth factors in urine from prostate cancer patients. FASEB Bioadv. [Epub ahead of print]. Application: Human urine.
Mossa AH et al. (2020). Imbalance of nerve growth factor metabolism in aging women with overactive bladder syndrome. World J Urol. [Epub ahead of print]. Application: Human urine.
Rowe CW et al. (2019). The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis. BMC Endocr Disord. 19(1):128. Application: Human serum.
Stapledon CJM et al. (2019). Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS One. 14(9):e0222602. Application: Human primary culture supernatant.
Ryu JC et al. (2018). Role of proNGF/p75 signaling in bladder dysfunction after spinal cord injury. J Clin Invest. [Epub ahead of print]. Application: Human urine.
Sherif IO & Al-Gayyar MMH (2018). Oleuropein potentiates anti-tumor activity of cisplatin against HepG2 through affecting proNGF/NGF balance. Life Sci. [Epub ahead of print]. Application: Human cell culture.